Data on this page show the responses of adolescent participants aged less than 20 years who received the AstraZeneca COVID-19 vaccine and completed an AusVaxSafety survey sent on day 3 after vaccination. These data provide you with a profile of what to expect in the days following your AstraZeneca COVID-19 vaccination and can assist when planning for your COVID-19 vaccination. Please note, the AstraZeneca COVID-19 vaccine is only approved for those aged 18 years and older in Australia.


The profile of reported events from AusVaxSafety surveillance of the AstraZeneca COVID-19 vaccine is similar to that reported in clinical trials and from post-marketing surveillance overseas.

There have been no reports of thrombosis thrombocytopenia syndrome (TTS) following COVID-19 vaccination reported to AusVaxSafety. For more information on all vaccine safety monitoring in Australia and on TTS, see weekly TGA safety updates

AusVaxSafety's active vaccine safety surveillance system complements the TGA's enhanced safety surveillance activities. Find out more about how the TGA monitors the safety of COVID-19 vaccines and how you can report side effects on the TGA website.

Read more about how AusVaxSafety is conducting national COVID-19 vaccine safety surveillance in Australia here.

Links to further information on the expected profile for the AstraZeneca COVID-19 vaccine are available below: 

AusVaxSafety will continue to closely monitor the safety data of all COVID-19 vaccines in use in Australia in conjunction with the TGA.

Last updated August 2022